Pigment Epithelial Detachment Clinical Trial
Official title:
Intravitreal Ranibizumab in Patients With Retinal Pigment Epithelial Detachments Secondary to Age-related Macular Degeneration
The purpose of this study is to demonstrate the efficacy of ranibizumab in patients with retinal pigment epithelial detachment secondary to age-related macular degeneration (AMD).
Pigment epithelial detachments (PED) secondary to age-related macular degeneration (AMD) have been excluded from practically all study populations of ranibizumab studies so far. PED represents a special entity in AMD. As yet, no standard treatment has been established for this disease.The stimuli that induce PED are not very well known, but there is evidence suggesting that angiogenic factors such as vascular endothelial growth factor (VEGF) also play a role in the pathogenesis. Ranibizumab is an anti-VEGF antibody fragment that blocks VEGF activity in patients with neovascular AMD. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00590694 -
Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments
|
Phase 2/Phase 3 | |
| Terminated |
NCT01334255 -
iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)
|
Phase 1 | |
| Completed |
NCT00841581 -
Lucentis to Treat Pigment Epithelial Detachment
|
Phase 2 | |
| Active, not recruiting |
NCT01670162 -
On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)
|
Phase 4 | |
| Completed |
NCT03370380 -
Aflibercept in Patients With Pigment Epithelial Detachments (PED)
|